These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 25027531)

  • 1. Pharmacist-managed protocol to implement simvastatin labeling changes in a family medicine clinic.
    Harris IM; Philbrick AM; Fallert CJ; Soliman AM
    Am J Health Syst Pharm; 2014 Aug; 71(15):1248-51. PubMed ID: 25027531
    [No Abstract]   [Full Text] [Related]  

  • 2. Team-based approach to addressing simvastatin safety concerns.
    Robinson M; Gunning K; Pippitt K; McAdam-Marx C; Jennings BT
    J Am Pharm Assoc (2003); 2013; 53(5):539-44. PubMed ID: 24030132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New statin labeling requirements: an overview.
    Hicks MR; Murphy BL
    Consult Pharm; 2013 Nov; 28(11):742-4. PubMed ID: 24217194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of pharmacists' interventions and simvastatin dose restrictions.
    Shoulders BR; Franks AS; Barlow PB; Williams JD; Farland MZ
    Ann Pharmacother; 2014 Jan; 48(1):54-61. PubMed ID: 24259645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Community pharmacists' views, attitudes and early experiences of over-the-counter simvastatin.
    Hansford D; Cunningham S; John D; McCaig D; Stewart D
    Pharm World Sci; 2007 Aug; 29(4):380-5. PubMed ID: 17357811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching statin therapy using a pharmacist-managed therapeutic conversion program versus usual care conversion among indigent patients.
    Miller AE; Hansen LB; Saseen JJ
    Pharmacotherapy; 2008 May; 28(5):553-61. PubMed ID: 18447653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmaceutical services in family practice medical residency training programs.
    Bendayan R; Robinson JD; Stewart RB
    Am J Hosp Pharm; 1983 Feb; 40(2):274-7. PubMed ID: 6829581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Avoiding patient morbidity: Updated statin drug interactions and risks for patient harm.
    Finks SW; Campbell JD
    Nurse Pract; 2014 Nov; 39(11):45-51. PubMed ID: 25325525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and economic outcomes in patients switched to simvastatin in a community-based family medicine practice.
    Willey VJ; Reinhold JA; Willey KH; Kelly BL; Cziraky MJ
    Int J Clin Pract; 2010 Aug; 64(9):1235-8. PubMed ID: 20653799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reclassification of simvastatin to over-the-counter status in the United Kingdom: a primary prevention strategy.
    Nash DB; Nash SA
    Am J Cardiol; 2004 Nov; 94(9A):35F-39F. PubMed ID: 15519290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simvastatin prescribing patterns before and after FDA dosing restrictions: a retrospective analysis of a large healthcare claims database.
    Tuchscherer RM; Nair K; Ghushchyan V; Saseen JJ
    Am J Cardiovasc Drugs; 2015 Feb; 15(1):27-34. PubMed ID: 25348907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistent use of against-label statin-fibrate combinations from 2003-2009 despite United States Food and Drug Administration dose restrictions.
    Alford JC; Saseen JJ; Allen RR; Nair KV
    Pharmacotherapy; 2012 Jul; 32(7):623-30. PubMed ID: 22570173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a pharmacist-managed lipid clinic.
    Cording MA; Engelbrecht-Zadvorny EB; Pettit BJ; Eastham JH; Sandoval R
    Ann Pharmacother; 2002 May; 36(5):892-904. PubMed ID: 11978169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On media report affecting statin use by the New Zealand public.
    Fitchett TE
    N Z Med J; 2006 Nov; 119(1245):U2326. PubMed ID: 17146495
    [No Abstract]   [Full Text] [Related]  

  • 15. Integration of pharmacists into a patient-centered medical home.
    Scott MA; Hitch B; Ray L; Colvin G
    J Am Pharm Assoc (2003); 2011; 51(2):161-6. PubMed ID: 21382805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lifestyle or life-saving medicines? A primary healthcare professional and consumer opinion survey on over-the-counter statins.
    Vamvakopoulos JE; Kountouri M; Marshall T; Greenfield SM
    Ann Pharmacother; 2008 Mar; 42(3):413-20. PubMed ID: 18303145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors.
    Yang SH; Choi JS; Choi DH
    Pharmacology; 2011; 88(1-2):1-9. PubMed ID: 21709429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Community pharmacists' experience with pharmacogenetic testing.
    Moaddeb J; Mills R; Haga SB
    J Am Pharm Assoc (2003); 2015; 55(6):587-594. PubMed ID: 26409205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simvastatin-induced lactic acidosis: a rare adverse reaction?
    Goli AK; Goli SA; Byrd RP; Roy TM
    Clin Pharmacol Ther; 2002 Oct; 72(4):461-4. PubMed ID: 12386648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous administration of HMG-CoA reductase inhibitors in hyperlipidaemic and normal rats.
    Joles J; Willekes-Koolschijn N; Koomans H; Van Tol A; Geelhoed-Mieras T; Crommelin D; Van Bloois L; Krajnc-Franken M; Cohen L; Griffioen M
    Lab Anim; 1992 Oct; 26(4):269-80. PubMed ID: 1447905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.